GenMont Biotech Incorporation Balance Sheet Health
Financial Health criteria checks 5/6
GenMont Biotech Incorporation has a total shareholder equity of NT$1.5B and total debt of NT$79.7M, which brings its debt-to-equity ratio to 5.4%. Its total assets and total liabilities are NT$1.7B and NT$189.6M respectively. GenMont Biotech Incorporation's EBIT is NT$45.7M making its interest coverage ratio -5.4. It has cash and short-term investments of NT$292.3M.
Key information
5.4%
Debt to equity ratio
NT$79.72m
Debt
| Interest coverage ratio | -5.4x |
| Cash | NT$292.26m |
| Equity | NT$1.49b |
| Total liabilities | NT$189.63m |
| Total assets | NT$1.68b |
Recent financial health updates
No updates
Recent updates
We Think That There Are More Issues For GenMont Biotech Incorporation (TWSE:3164) Than Just Sluggish Earnings
Mar 19
Should You Or Shouldn't You: A Dividend Analysis on GenMont Biotech Incorporation (TPE:3164)
Apr 04GenMont Biotech Incorporation's(TPE:3164) Share Price Is Down 26% Over The Past Five Years.
Feb 14
Is GenMont Biotech Incorporation's (TPE:3164) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 24Tread With Caution Around GenMont Biotech Incorporation's (TPE:3164) 3.5% Dividend Yield
Jan 03Are GenMont Biotech Incorporation's (TPE:3164) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 08Financial Position Analysis
Short Term Liabilities: 3164's short term assets (NT$493.2M) exceed its short term liabilities (NT$103.2M).
Long Term Liabilities: 3164's short term assets (NT$493.2M) exceed its long term liabilities (NT$86.5M).
Debt to Equity History and Analysis
Debt Level: 3164 has more cash than its total debt.
Reducing Debt: 3164's debt to equity ratio has increased from 0% to 5.4% over the past 5 years.
Debt Coverage: 3164's debt is well covered by operating cash flow (103.2%).
Interest Coverage: 3164 earns more interest than it pays, so coverage of interest payments is not a concern.